ArticleJournal of inflammation research2025
Nsun2 Knockdown Alleviates Asthma Progression by Inhibiting Hnrnpk Expression Through Decreased 5-Methylcytosine.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NOP2-mediated m5C methylation impairs mitophagy and aggravates acute lung injury by targeting PINK1.Scientific reports · 2026Article
- A Comprehensive Review of Epigenetic Regulation of Vascular Smooth Muscle Cells During Development and Disease.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Asthma is a chronic inflammatory airway disease. 5-methylcytosine (m5C), an RNA modification, plays an unclear role in asthma pathogenesis. This study aimed to investigate the mechanism of m5C modification in asthma development. Methods: Ovalbumin (OVA)-challenged BALB/c mice and PDGF-BB-stimulated airway smooth muscle cells (ASMCs) were used as in vivo and in vivo asthma models, respectively. Lung pathology was assessed through hematoxylin-eosin staining, inflammatory cell counts, and cytokine analysis in bronchoalveolar lavage fluid (BALF). Colony formation assays, ELISA, and transwell assays were conducted to evaluate cell proliferation, migration, invasion, and inflammatory responses in ASMCs. Mechanistic studies included methylated RNA immunoprecipitation (MeRIP), RNA immunoprecipitation (RIP), and dual-luciferase reporter assays. Results: The asthma mouse model showed exacerbated lung injury and inflammation, accompanied by increased m5C levels and Nsun2 expression. Nsun2 knockdown suppressed PDGF-BB-induced ASMC proliferation, migration, invasion, and inflammatory responses through reduced Hnrnpk mRNA stability mediated by decreased m5C modification. Hnrnpk overexpression reversed the inhibitory effects of Nsun2 knockdown in PDGF-BB-treated ASMCs. Moreover, Nsun2 knockdown ameliorated airway inflammation and lung injury in asthmatic mice. Conclusion: Nsun2 knockdown alleviated asthma by downregulating Hnrnpk expression through m5C-dependent regulation, providing novel mechanistic insights and potential therapeutic targets for asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.